Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00689104 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2336

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: Mirabegron
DRUG: Tolterodine
DRUG: Placebo to Mirabegron
DRUG: Placebo to Tolterodine

Sponsor

Astellas Pharma Inc